Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care oncology prior auth Policy Update | O…
    Ask Trek AI about this page
    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Requires review by Evolent for oncology medications and supportive agents for Medicare - Wellcare by Fidelis Care participating providers before dispensing or administration in outpatient/ambulatory settings; lists HCPCS/CPT codes and preferred biosimilars. Affects providers submitting oncology regimens for members in North Carolina.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateFeb 1, 2025
    Next Review DateN/A
    Key ActionSubmit the full oncology regimen and supporting clinical information to Evolent for review prior to dispensing or administration.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+oncology and supportive drug codes listed
    Evolent reviewprior authorization required for listed agents
    Medical & Pharmacybilling: medical & pharmacy
    Preferred agentspreferred biosimilars listed

    Coverage Criteria

    Prior authorization / review conditions

    Covered when the following administrative conditions are met

    Evolent review and submission: The entire oncology regimen must be submitted to Evolent for review before dispensing or administration.

    Includes clinical trials; applies to participating providers and members of all ages. Submit via Evolent web portal or phone; non-participating providers submit to the plan via fax.

    Approved indication and benefit assignment: Evolent will review to establish use for a medically accepted indication and determine whether the agent is assigned to the medical or pharmacy benefit.

    Providers should include preferred biosimilar selection when applicable.

    The policy excludes certain requests from submission to Evolent. Do NOT submit the following items: antibiotics; bone marrow, stem cell transplants, and CAR‑T cell therapy; controlled substances (e.g., morphine); equipment requests such as infusion pumps; genetic laboratory testing and laboratory services; hemophilia drugs; inpatient drug requests; inpatient radiation and chemotherapy treatments; iron preparations; radiopharmaceuticals; surgeries/surgical procedures; sickle cell diagnoses and therapies; and immune globulins.

    Coding / Billing Codes

    Selected medical benefit HCPCS/CPT codes (list continues in document)mixedCovered
    C9173FIGRASTIM-TXID (NYPOZI)
    J0897DENOSUMAB XGEVA
    C9293GLUCARPIDASE
    J1010
    J0185APREPITANT INJ
    Medical/injectable oncology agentsHCPCSCovered
    J1950LEUPROLIDE ACETATE INJ
    J2506PEGFILGRASTIM (ON-BODY INJECTOR)
    J9035BEVACIZUMAB 10 MG
    J9040BLINATUMOMAB
    J9056BENDAMUSTINE (various descriptors in list)
    Pharmacy/oral oncology agents (pharmacy benefit only section)HCPCSCovered
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL
    J8999MANY ORAL ONCOLOGY AGENTS (numerous specific agents listed under J8999)
    J9216INTERFERON GAMMA 1B

    Provider Actions & Requirements

    Prior Authorization

    Prior Authorization Required

    Oncology medications and supportive agents require prior review by Evolent for participating providers before dispensing at a pharmacy or administration in physician offices, outpatient hospitals, or ambulatory settings. Submit requests to Evolent's web portal at my.newcenturyhealth.com or call 1-888-999-7713 (option 1). Non‑participating providers must submit requests to the plan via fax: 1-844-235-5090.

    • Evolent Web portal: my.newcenturyhealth.com
    • Phone: 1-888-999-7713, option 1
    • Non‑participating provider fax (plan): 1-844-235-5090
    Denial Risk

    Submit Entire Oncology Regimen

    Please submit the entire oncology regimen to Evolent for review — not just selected agents. Failure to submit the complete regimen may result in denial of coverage.

    Initial Prior Authorization Criteria

    Initial prior authorization

    Initial authorization requirement

    Submission: Submit the entire oncology regimen and clinical rationale to Evolent prior to dispensing or administration.

    Includes identification of whether each agent is medical or pharmacy benefit; omissions may result in a denial.

    Site of Care Requirements

    Prior Authorization

    Site-of-care prior review required

    Evolent review is required before dispensing at a pharmacy or before administration in a physician office, outpatient hospital, or ambulatory setting.

    Preferred Biosimilars

    Billing Rule

    Trastuzumab — preferred biosimilars and pharmacy notes

    Preferred medical‑benefit trastuzumab biosimilar: Trazimera; pharmacy benefit includes Herceptin and multiple trastuzumab biosimilars (Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera).

    Billing Rule

    Bevacizumab — preferred biosimilars and pharmacy notes

    Preferred medical‑benefit bevacizumab biosimilars: Mvasi and Zirabev; pharmacy benefit includes Avastin and the listed biosimilars (Mvasi, Zirabev).

    Billing Rule

    Rituximab — preferred biosimilars and pharmacy notes

    Preferred medical‑benefit rituximab biosimilars include Ruxience and Truxima; pharmacy benefit products include Riabni, Rituxan, Rituxan Hycela, Ruxience, and Truxima.

    Definitions

    Evolent review — prior authorization/review process
    DefinitionEvolent review: prior authorization/review process conducted by Evolent to establish medical necessity and determine medical vs pharmacy benefit for oncology medications and supportive agents before dispensing or administration.
    When requiredFor all participating providers prior to dispensing at a pharmacy or administration in a physician office, outpatient hospital, or ambulatory setting for members of all ages.
    What to submitThe entire oncology regimen (including preferred biosimilars when applicable) and supporting clinical information for review.
    How to submitVia Evolent's web portal at my.newcenturyhealth.com or by phone at 1-888-999-7713, option 1; non‑participating providers submit to the plan via fax 1-844-235-5090.
    Clinical trialsClinical trial requests may be submitted to Evolent for review under the same process.

    Background

    Oncology medications and supportive agents commonly require prior authorization to confirm that use is for a medically accepted indication and to determine appropriate benefit assignment (medical vs. pharmacy). For Medicare — Wellcare by Fidelis Care participating providers, Evolent review is required before dispensing at a pharmacy or administration in a physician office, outpatient hospital, or other ambulatory setting. Providers should submit the entire oncology regimen to Evolent for review; failure to include the full regimen may result in denial. Preferred biosimilars for several classes are identified and should be included in the submission for consideration.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateFeb 1, 2025
    Next Review DateN/A
    Key ActionSubmit the full oncology regimen and supporting clinical information to Evolent for review prior to dispensing or administration.
    SourceLink
    On This Page
    Coverage CriteriaCoding / Billing CodesProvider Actions & RequirementsInitial Prior Authorization CriteriaSite of Care RequirementsPreferred BiosimilarsDefinitionsBackground
    • Submit all agents, supportive drugs, and regimen components together
    • This applies regardless of whether individual drugs appear to require prior authorization
    Note

    Preferred Biosimilars — Send to Evolent

    Evolent reviews preferred biosimilar agents for oncology indications as noted in the plan formulary guidance. When a biosimilar is the preferred agent, providers should still send that preferred biosimilar to Evolent for review.

    • Preferred erythropoiesis‑stimulating: Retacrit (medical); Procrit (pharmacy)
    • Preferred trastuzumab biosimilar (medical): Trazimera; pharmacy options include Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera
    • Preferred bevacizumab biosimilars (medical): Mvasi, Zirabev; pharmacy: Avastin, Mvasi, Zirabev
    • Hematopoietic agents (medical & pharmacy): Zarxio
    • Rituximab (medical): Ruxience, Truxima
    Documentation Required

    How to Submit — Required Regimen Details

    When submitting prior authorization requests include complete regimen details (all drugs, dosing, schedule, indication, and intent of therapy). Use the web portal or phone submission channels described above. Incomplete submissions or omission of regimen components increase the risk of denial or delays.

    • Required details: drug names (including biosimilars), dose, route, frequency, number of cycles, clinical indication, and relevant supporting documentation
    • Submission channels: Evolent web portal and phone (see Prior Authorization Required callout)